Published in J Mol Cell Cardiol on July 06, 2015
Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor. Br J Pharmacol (2016) 0.75
Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking. Biochem Pharmacol (2016) 0.75
Non-invasive phenotyping and drug testing in single cardiomyocytes or beta-cells by calcium imaging and optogenetics. PLoS One (2017) 0.75
Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One (2017) 0.75
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med (1991) 13.91
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A (2000) 4.06
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J (1998) 3.83
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol (2009) 2.98
High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol (1996) 1.91
Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci (2005) 1.90
Pharmacology of cardiac potassium channels. Cardiovasc Res (2004) 1.90
Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol (2000) 1.89
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. Circ Res (2015) 1.77
The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther (2008) 1.72
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol (2006) 1.68
Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med (2003) 1.65
Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A (2002) 1.51
Molecular determinants of HERG channel block. Mol Pharmacol (2006) 1.49
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace (2010) 1.43
Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. Cardiovasc Res (1997) 1.42
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol (2003) 1.41
Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation (1990) 1.38
Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol (2003) 1.37
HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods (2005) 1.35
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping. Mol Pharmacol (2004) 1.17
Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace (2011) 1.14
The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C. Biochem Biophys Res Commun (2005) 1.08
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol (2008) 1.07
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. Mol Pharmacol (2001) 1.07
Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol (2008) 1.07
Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci (2008) 1.05
Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol (2005) 1.03
Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. J Mol Cell Cardiol (1996) 0.98
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol (2002) 0.98
Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin. Am J Physiol (1989) 0.96
Flecainide. J Cardiovasc Electrophysiol (1994) 0.95
States and sites of actions of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol (1992) 0.95
Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ (2011) 0.95
hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel (2010) 0.91
Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res (1992) 0.90
Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis. J Cardiovasc Electrophysiol (2011) 0.89
Antiarrhythmics--from cell to clinic: past, present, and future. Heart (2000) 0.89
Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands. Biochim Biophys Acta (2013) 0.89
The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol (2007) 0.89
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block. J Chem Inf Model (2014) 0.88
Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol (2011) 0.88
The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol (2009) 0.86
Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. Arzneimittelforschung (2002) 0.85
The hERG K(+) channel S4 domain L532P mutation: characterization at 37°C. Biochim Biophys Acta (2011) 0.85
Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs. Novartis Found Symp (2005) 0.81
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants. J Mol Cell Cardiol (2014) 0.81
Multiple modes of ryanodine receptor 2 inhibition by flecainide. Mol Pharmacol (2014) 0.80
Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.80
Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. J Pharmacol Toxicol Methods (2007) 0.79
Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1. J Biol Chem (2010) 0.78
Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol (2003) 0.78
Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel. PLoS One (2012) 0.78
Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl (2000) 0.78
Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine. Anesthesiology (2007) 0.77
An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. Pharmacotherapy (2014) 0.76
Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia. Pacing Clin Electrophysiol (2010) 0.76
Flecainide associated torsade de pointes: A potential case of reverse use dependence. J Res Med Sci (2013) 0.76